Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15286161 | 0.91 | MAPT (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16147632 | 0.82 | FABP4 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27795815 | 0.78 | MAPT (0.50) | CNR2MAPTKAT2B | |
| SCHEMBL17482044 | 0.78 | TP53 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16558097 | 0.77 | MEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29937390 | 0.77 | ALDH1A1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27795794 | 0.76 | MAPT (0.48) | MAPTKAT2B | |
| SCHEMBL15286444 | 0.75 | FABP4 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1921483 | 0.75 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29937363 | 0.75 | CNR2 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| EP-2968270-A2 | MODULATION OF K2P CHANNELS | The Regents of The University of California (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165307-A9 | MODULATION OF K2P CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014165307-A9 | MODULATION OF K2P CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014165307-A2 | MODULATION OF K2P CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165307-A2 | MODULATION OF K2P CHANNELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | KCNJ2, KCNK2, KCNN3 | PSEN1 276/4885PSEN2 143/4885APH1B 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.